Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Efforts to define either a biomarker for irritable bowel syndrome (IBS) or a valid animal model have proven disappointing. The aims of this study were to determine if buspirone stimulates prolactin release through the 5-hydroxytryptamine (5HT)1a receptor and whether this response is altered in patients with IBS and in the rat maternal separation model. Buspirone (30 mg) was used to stimulate prolactin release in 40 patients with IBS and in 40 healthy controls. In study 1, 10 IBS patients and 10 controls underwent pretreatment with pindolol (5HT1a antagonist) or placebo followed by buspirone. In study 2, 30 patients with IBS and 30 healthy controls had prolactin release stimulated by buspirone. Maternally separated and nonseparated rats were also treated with buspirone and prolactin monitored. Serotonin metabolites were measured together with the expression of the 5HT1a and serotonin transporter (SERT) gene. Pindolol produced a dose-dependent decrease in the buspirone prolactin response. Patients with IBS and maternally separated rats showed an exaggerated release of prolactin in response to buspirone. In the animal model, an increased turnover of 5HT was found in the brainstem together with a trend toward increased activity of the SERT gene. In conclusion altered central serotonin responses are found in both IBS and in an animal model.
 ...
PMID:Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. 1819 52

Irritable bowel syndrome (IBS) is considered to be a physical disorder that mainly affects the bowel and is clinically characterized by lower abdominal pain or discomfort, diarrhea, constipation (or alternating diarrhea/constipation), gas, bloating, and nausea. According to recent studies, it appears that there is an association with increased prolactin levels in patients suffering from IBS. We report a rare case of regression of IBS symptoms (constipation type) in a 16-year-old female adolescent after receiving cabergoline for treating hyperprolactinemia due to pituitary macroadenoma. Our hypothesis is that increased prolactin levels, for instance due to a pituitary adenoma, may suppress prolactin-releasing peptide release and lead to a reverse feedback interaction, consequently resulting in oversecretion of cholecystokinin, inducing the development of IBS.
 ...
PMID:Constipation-predominant irritable bowel syndrome associated to hyperprolactinemia. 2208 83

A middle-aged woman was referred under the 2-week urgent brain cancer initiative following the finding of a raised serum prolactin level. The patient had been taking metoclopramide on a daily basis to aid her symptoms of irritable bowel syndrome. The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication.
 ...
PMID:Pharmacological hyperprolactinaemia. 2214 Apr 13